A resource for subjects enrolled in the TRANSCEND clinical trial

Thank you for enrolling in the TRANSCEND clinical trial. You have chosen to give the extraordinary gift of participating in this clinical study, contributing valuable information to researchers about peripheral artery disease (PAD) and possibly aiding the development of new therapies. 

We’ve developed this site as a resource for trial participants. You can learn more about PAD, the TRANSCEND trial and the SurVeil™ drug-coated balloon being investigated in this study. 

 
treatpad_mission.png
 
 
We want to learn more about PAD and ultimately improve treatment of this condition. Information collected during follow-up appointments moves us toward that goal.

THANK YOU FOR YOUR COMMITMENT TO THE TRANSCEND TRIAL!
 
treatpad_nurse.jpg

ENROLLMENT STATUS:

The TRANSCEND clinical trial reached its enrollment goal of 446 subjects on 08/17/2019. Find out why your follow-up appointments are key to our success!

treatpad_couple.jpg

FOR PATIENTS: ABOUT PAD

Learn more about PAD, PAD treatment, the TRANSCEND clinical trial and the SurVeil™ drug-coated balloon.

treatpad_lady.jpg

CLINICALTRIALS.GOV

Visit clinicaltrials.gov, a database of privately and publicly funded clinical studies, for up-to-date information on the current status of the TRANSCEND clinical trial.

CAUTION Investigational device. Limited by Federal (or United States) law to investigational use.

SURVEIL is a registered trademark of Surmodics, Inc. and/or its affiliates.

©2019 Surmodics, Inc. All rights reserved.

treatpad_transcend_logo.png